France · Delayed Price · Currency is EUR Transgene Statistics
Total Valuation
Transgene has a market cap or net worth of EUR 191.72 million. The enterprise value is 101.06 million.
| Market Cap | 191.72M |
| Enterprise Value | 101.06M |
Important Dates
The last earnings date was Thursday, September 24, 2026.
| Earnings Date | Sep 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Transgene has 273.88 million shares outstanding. The number of shares has increased by 61.52% in one year.
| Current Share Class | 273.88M |
| Shares Outstanding | 273.88M |
| Shares Change (YoY) | +61.52% |
| Shares Change (QoQ) | +18.14% |
| Owned by Insiders (%) | 78.61% |
| Owned by Institutions (%) | 0.24% |
| Float | 48.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 34.09 |
| PB Ratio | 1.76 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.40, with a Debt / Equity ratio of 0.02.
| Current Ratio | 9.40 |
| Quick Ratio | 8.83 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -26.54 |
Financial Efficiency
Return on equity (ROE) is -64.21% and return on invested capital (ROIC) is -31.28%.
| Return on Equity (ROE) | -64.21% |
| Return on Assets (ROA) | -26.24% |
| Return on Invested Capital (ROIC) | -31.28% |
| Return on Capital Employed (ROCE) | -30.52% |
| Weighted Average Cost of Capital (WACC) | 8.50% |
| Revenue Per Employee | 38,786 |
| Profits Per Employee | -233,779 |
| Employee Count | 145 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.05% in the last 52 weeks. The beta is 0.69, so Transgene's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -38.05% |
| 50-Day Moving Average | 0.79 |
| 200-Day Moving Average | 0.81 |
| Relative Strength Index (RSI) | 23.79 |
| Average Volume (20 Days) | 116,599 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Transgene had revenue of EUR 5.62 million and -33.90 million in losses. Loss per share was -0.16.
| Revenue | 5.62M |
| Gross Profit | -28.27M |
| Operating Income | -34.74M |
| Pretax Income | -33.90M |
| Net Income | -33.90M |
| EBITDA | -33.40M |
| EBIT | -34.74M |
| Loss Per Share | -0.16 |
Balance Sheet
The company has 92.84 million in cash and 2.18 million in debt, with a net cash position of 90.66 million or 0.33 per share.
| Cash & Cash Equivalents | 92.84M |
| Total Debt | 2.18M |
| Net Cash | 90.66M |
| Net Cash Per Share | 0.33 |
| Equity (Book Value) | 109.20M |
| Book Value Per Share | 0.42 |
| Working Capital | 89.88M |
Cash Flow
In the last 12 months, operating cash flow was -38.66 million and capital expenditures -1.20 million, giving a free cash flow of -39.86 million.
| Operating Cash Flow | -38.66M |
| Capital Expenditures | -1.20M |
| Depreciation & Amortization | 1.34M |
| Net Borrowing | n/a |
| Free Cash Flow | -39.86M |
| FCF Per Share | -0.15 |
Margins
| Gross Margin | n/a |
| Operating Margin | -617.69% |
| Pretax Margin | -602.74% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Transgene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -61.52% |
| Shareholder Yield | -61.52% |
| Earnings Yield | -17.68% |
| FCF Yield | -20.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |